The Company anticipates that an interim analysis of the complete 30-day follow-up data on the first half (50%) of patients enrolled in the trial will be completed in the first quarter of 2010. Further, the Company anticipates completing enrollment in and having top-line data available from this trial in the second half of 2010.
#2 -
ROTH CAPITAL PARTNERS TO HOLD 22ND ANNUAL OC GROWTH STOCK CONFERENCE - March 15-17, 2010